Clementia Pharmaceuticals, a clinical-stage biotech focused on treating ultra-rare bone diseases, raised $120 million by offering 8 million shares at $15, the high end of the range of $13 to $15. The company had previously planned to offer 7.15 million shares. Insiders had indicated an interest in buying up to $30 million on the IPO, representing 25% of the deal. Clementia Pharmaceuticals plans to list on the Nasdaq under the symbol CMTA. Morgan Stanley and Leerink Partners acted as lead managers on the deal.
